Build Your Comparison

Side-by-side financial analysis
QTTB logo
QTTB
LLY logo
LLY
JPM logo
JPM
Try popular comparisons:

Stock Comparison

QTTB vs LLY vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
QTTB
Q32 Bio Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$162M
5Y Perf.-95.4%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.10T
5Y Perf.+590.1%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$875.80B
5Y Perf.+218.2%

QTTB vs LLY vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
QTTB logoQTTB
LLY logoLLY
JPM logoJPM
IndustryBiotechnologyDrug Manufacturers - GeneralBanks - Diversified
Market Cap$162M$1.10T$875.80B
Revenue (TTM)$54M$72.25B$280.33B
Net Income (TTM)$33M$25.27B$57.05B
Gross Margin99.5%83.5%60.0%
Operating Margin39.8%45.9%25.9%
Forward P/E5.2x31.7x14.1x
Total Debt$15M$42.50B$942.38B
Cash & Equiv.$48M$7.16B$343.34B

QTTB vs LLY vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

QTTB
LLY
JPM
StockJun 20Jun 26Return
Q32 Bio Inc. (QTTB)1004.6-95.4%
Eli Lilly and Compa… (LLY)100690.1+590.1%
JPMorgan Chase & Co. (JPM)100318.2+218.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: QTTB vs LLY vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: QTTB leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. JPMorgan Chase & Co. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇QTTB emerged as the overall leader. Track its performance:
QTTB
Q32 Bio Inc.
The Defensive Pick

QTTB carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.

  • Lower volatility, beta 0.62, Low D/E 36.5%, current ratio 4.85x
  • 156.7% revenue growth vs JPM's 3.3%
  • 61.9% margin vs JPM's 20.4%
Best for: sleep-well-at-night
LLY
Eli Lilly and Company
The Growth Play

LLY is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
  • 15.2% 10Y total return vs JPM's 454.4%
  • Beta 0.53, yield 0.5%, current ratio 1.58x
Best for: growth exposure and long-term compounding
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is income & stability and valuation efficiency.

  • Dividend streak 15 yrs, beta 0.95, yield 1.9%
  • PEG 1.08 vs LLY's 1.10
  • Lower P/E (14.1x vs 31.7x), PEG 1.08 vs 1.10
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthQTTB logoQTTB156.7% revenue growth vs JPM's 3.3%
ValueJPM logoJPMLower P/E (14.1x vs 31.7x), PEG 1.08 vs 1.10
Quality / MarginsQTTB logoQTTB61.9% margin vs JPM's 20.4%
Stability / SafetyLLY logoLLYBeta 0.53 vs JPM's 0.95, lower leverage
DividendsJPM logoJPM1.9% yield, 15-year raise streak, vs LLY's 0.5%, (1 stock pays no dividend)
Momentum (1Y)QTTB logoQTTB+6.5% vs JPM's +19.1%
Efficiency (ROA)QTTB logoQTTB53.3% ROA vs JPM's 1.3%

QTTB vs LLY vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
QTTBQ32 Bio Inc.

Segment breakdown not available.

LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

QTTB vs LLY vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGLLY

Income & Cash Flow (Last 12 Months)

Evenly matched — QTTB and LLY each lead in 2 of 5 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 5216.8x QTTB's $54M. QTTB is the more profitable business, keeping 61.9% of every revenue dollar as net income compared to JPM's 20.4%.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$54M$72.2B$280.3B
EBITDAEarnings before interest/tax$22M$34.7B$81.4B
Net IncomeAfter-tax profit$33M$25.3B$57.0B
Free Cash FlowCash after capex-$27M$13.6B$100.9B
Gross MarginGross profit ÷ Revenue+99.5%+83.5%+60.0%
Operating MarginEBIT ÷ Revenue+39.8%+45.9%+25.9%
Net MarginNet income ÷ Revenue+61.9%+35.0%+20.4%
FCF MarginFCF ÷ Revenue-51.0%+18.8%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+55.5%
EPS Growth (YoY)Latest quarter vs prior year+40.0%+169.9%+16.0%
Evenly matched — QTTB and LLY each lead in 2 of 5 comparable metrics.

Valuation Metrics

JPM leads this category, winning 4 of 7 comparable metrics.

At 5.2x trailing earnings, QTTB trades at a 90% valuation discount to LLY's 50.6x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 1.20x vs LLY's 1.76x — a lower PEG means you pay less per unit of expected earnings growth.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$162M$1.10T$875.8B
Enterprise ValueMkt cap + debt − cash$129M$1.13T$1.47T
Trailing P/EPrice ÷ TTM EPS5.25x50.59x15.64x
Forward P/EPrice ÷ next-FY EPS est.31.74x14.08x
PEG RatioP/E ÷ EPS growth rate1.76x1.20x
EV / EBITDAEnterprise value multiple7.48x36.22x18.11x
Price / SalesMarket cap ÷ Revenue3.02x16.83x3.13x
Price / BookPrice ÷ Book value/share3.72x39.29x2.42x
Price / FCFMarket cap ÷ FCF122.26x8.68x
JPM leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

QTTB leads this category, winning 5 of 9 comparable metrics.

QTTB delivers a 2.3% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $16 for JPM. QTTB carries lower financial leverage with a 0.37x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs QTTB's 4/9, reflecting strong financial health.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+2.3%+101.2%+15.9%
ROA (TTM)Return on assets+53.3%+22.7%+1.3%
ROICReturn on invested capital+41.8%+4.5%
ROCEReturn on capital employed+26.8%+46.6%+8.9%
Piotroski ScoreFundamental quality 0–9485
Debt / EquityFinancial leverage0.37x1.60x2.60x
Net DebtTotal debt minus cash-$33M$35.3B$599.0B
Cash & Equiv.Liquid assets$48M$7.2B$343.3B
Total DebtShort + long-term debt$15M$42.5B$942.4B
Interest CoverageEBIT ÷ Interest expense21.88x35.68x0.74x
QTTB leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $52,914 today (with dividends reinvested), compared to $984 for QTTB. Over the past 12 months, QTTB leads with a +647.1% total return vs JPM's +19.1%. The 3-year compound annual growth rate (CAGR) favors LLY at 38.3% vs QTTB's -14.3% — a key indicator of consistent wealth creation.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+269.2%+7.8%-2.8%
1-Year ReturnPast 12 months+647.1%+44.4%+19.1%
3-Year ReturnCumulative with dividends-37.0%+164.5%+133.1%
5-Year ReturnCumulative with dividends-90.2%+429.1%+110.0%
10-Year ReturnCumulative with dividends-96.2%+1522.5%+454.4%
CAGR (3Y)Annualised 3-year return-14.3%+38.3%+32.6%
LLY leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — QTTB and LLY each lead in 1 of 2 comparable metrics.

LLY is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than JPM's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 98.2% from its 52-week high vs QTTB's 85.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.50x0.53x0.95x
52-Week HighHighest price in past year$14.85$1182.73$337.25
52-Week LowLowest price in past year$1.35$623.78$262.71
% of 52W HighCurrent price vs 52-week peak+85.5%+98.2%+93.0%
RSI (14)Momentum oscillator 0–10065.266.854.8
Avg Volume (50D)Average daily shares traded824K2.6M7.0M
Evenly matched — QTTB and LLY each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: QTTB as "Hold", LLY as "Buy", JPM as "Buy". Consensus price targets imply 9.1% upside for LLY (target: $1266) vs 6.3% for QTTB (target: $14). For income investors, JPM offers the higher dividend yield at 1.90% vs LLY's 0.52%.

MetricQTTB logoQTTBQ32 Bio Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$13.50$1266.17$338.78
# AnalystsCovering analysts84561
Dividend YieldAnnual dividend ÷ price+0.5%+1.9%
Dividend StreakConsecutive years of raises1115
Dividend / ShareAnnual DPS$6.00$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.4%+3.9%
JPM leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

JPM leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). QTTB leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 2 of 6 categories
Loading custom metrics...

QTTB vs LLY vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is QTTB or LLY or JPM a better buy right now?

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Q32 Bio Inc. (QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — QTTB or LLY or JPM?

On trailing P/E, Q32 Bio Inc.

(QTTB) is the cheapest at 5. 2x versus Eli Lilly and Company at 50. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus Eli Lilly and Company's 1. 10x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — QTTB or LLY or JPM?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +429.

1%, compared to -90. 2% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: LLY returned +1522% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — QTTB or LLY or JPM?

By beta (market sensitivity over 5 years), Q32 Bio Inc.

(QTTB) is the lower-risk stock at 0. 50β versus JPMorgan Chase & Co. 's 0. 95β — meaning JPM is approximately 89% more volatile than QTTB relative to the S&P 500. On balance sheet safety, Q32 Bio Inc. (QTTB) carries a lower debt/equity ratio of 37% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — QTTB or LLY or JPM?

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Q32 Bio Inc. grew EPS 136. 8% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, QTTB leads at 100. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — QTTB or LLY or JPM?

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus 20. 4% for JPMorgan Chase & Co. — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 26. 0% for JPM. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is QTTB or LLY or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus Eli Lilly and Company's 1. 10x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 1x forward P/E versus 31. 7x for Eli Lilly and Company — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 9. 1% to $1266. 17.

08

Which pays a better dividend — QTTB or LLY or JPM?

In this comparison, JPM (1.

9% yield), LLY (0. 5% yield) pay a dividend. QTTB does not pay a meaningful dividend and should not be held primarily for income.

09

Is QTTB or LLY or JPM better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1522% 10Y return). Both have compounded well over 10 years (LLY: +1522%, QTTB: -96. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between QTTB and LLY and JPM?

These companies operate in different sectors (QTTB (Healthcare) and LLY (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QTTB is a small-cap deep-value stock; LLY is a mega-cap high-growth stock; JPM is a large-cap deep-value stock. LLY, JPM pay a dividend while QTTB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.